• Users Online: 255
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2013  |  Volume : 33  |  Issue : 1  |  Page : 28-31

Evaluation of plasma-transforming growth factor-β1 in active-phase Peyronie’s disease

1 Department of Dermatology, Venerology and Andrology, Al-Azhar University for Boys, Cairo, Egypt
2 Department of Clinical Pathology, Al-Azhar University for Girls, Cairo, Egypt

Correspondence Address:
Mohamed I. Kamel
MD, Department of Dermatology, Venerology and Andrology, Al-Azhar University for Boys, 115 Manial street, PO Box 44555, Cairo
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.7123/01.EJDV.0000431535.86674.97

Rights and Permissions


Peyronie’s disease (PD) is an acquired disorder of the penile tunica albuginea. PD may manifest in the form of palpable penile plaques, penile curvature, erectile dysfunction, and/or painful erections, all of which carry significant morbidity and psychological distress for both patients and partners. The underlying etiopathogenesis of PD is not well understood but is thought to be caused by injury to the penis, usually through sexual activity. The study of transforming growth factor-β (TGF-β) is of particular interest in the identification of the pathophysiological mechanisms involved in PD tunical fibroses and in the activation of inflammatory cytokines and fibrosis-associated cytokines.


The aim of the study was to determine and evaluate the plasma TGF-β1 level in patients with active-phase PD compared with control individuals and determine the association between TGF-β1 level and disease activity.


The study was carried out on 30 patients with clinically suspected and ultrasonographically confirmed PD, and the results were compared with 20 matched healthy individuals who formed the control group. All participants were subjected to full history taking, clinical examination, ultrasonographic evaluation, and measurement of plasma TGF-β1 levels.


A significant increase in plasma TGF-β1 levels was found in active-phase PD patients when compared with controls, especially in patients suffering from pain and deformity and patients with associated comorbidities such as diabetes or hypertension (P<0.05).


Assessment of plasma TGF-β1 levels from peripheral blood samples is a simple method for detecting cavernous TGF-β1 expression without the need for penile blood samples. TGF-β1 may be a marker for PD.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded117    
    Comments [Add]    

Recommend this journal